Advanced search

Online first
Review paper
Published online: 2025-02-27

open access

View PDF Download PDF file
Page views 192
Article views/downloads 134
Get Citation

Connect on Social Media

Connect on Social Media

From potential to practice: Overcoming the immaturity of iPSC-derived cardiomyocytes for regenerative medicine

Ewelina Krogulec1, Aneta M Dobosz1, Nataniel Stefanowski1, Maria E Kendziorek1, Justyna Janikiewicz1, Agnieszka Dobrzyń1
DOI: 10.33963/v.phj.104577
Pubmed: 40066964

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385(9963): 117–171.
    CrossRefPubMed
  2. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol. 2005; 23(7): 845–856.
    CrossRefPubMed
  3. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002; 3(5): 349–363.
    CrossRefPubMed
  4. Gill JK, Rehsia SK, Verma E, et al. Stem cell therapy for cardiac regeneration: past, present, and future. Can J Physiol Pharmacol. 2024; 102(3): 161–179.
    CrossRefPubMed
  5. Huang Y, Wang T, López ME, et al. Recent advancements of human iPSC derived cardiomyocytes in drug screening and tissue regeneration. Microphysiol Syst. 2020; 4: 2.
    CrossRefPubMed
  6. Fuerstenau-Sharp M, Zimmermann ME, Stark K, et al. Generation of highly purified human cardiomyocytes from peripheral blood mononuclear cell-derived induced pluripotent stem cells. PLoS One. 2015; 10(5): e0126596.
    CrossRefPubMed
  7. Yin X, Li Q, Shu Y, et al. Exploiting urine-derived induced pluripotent stem cells for advancing precision medicine in cell therapy, disease modeling, and drug testing. J Biomed Sci. 2024; 31(1): 47.
    CrossRefPubMed
  8. Hsueh YC, Pratt RE, Dzau VJ, et al. Novel method of differentiating human induced pluripotent stem cells to mature cardiomyocytes via Sfrp2. Sci Rep. 2023; 13(1): 3920.
    CrossRefPubMed
  9. Breckwoldt K, Letuffe-Brenière D, Mannhardt I, et al. Differentiation of cardiomyocytes and generation of human engineered heart tissue. Nat Protoc. 2017; 12(6): 1177–1197.
    CrossRefPubMed
  10. Lian X, Zhang J, Azarin SM, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc. 2013; 8(1): 162–175.
    CrossRefPubMed
  11. Lian X, Hsiao C, Wilson G, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A. 2012; 109(27): E1848–E1857.
    CrossRefPubMed
  12. Wu P, Deng G, Sai X, et al. Maturation strategies and limitations of induced pluripotent stem cell-derived cardiomyocytes. Biosci Rep. 2021; 41(6): BSR20200833.
    CrossRefPubMed
  13. Denning C, Borgdorff V, Crutchley J, et al. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform. Biochim Biophys Acta. 2016; 1863(7 Pt B): 1728–1748.
    CrossRefPubMed
  14. Yang X, Pabon L, Murry CE. Engineering adolescence: Maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res. 2014; 114(3): 511–523.
    CrossRefPubMed
  15. Lopaschuk GD, Jaswal JS. Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J Cardiovasc Pharmacol. 2010; 56(2): 130–140.
    CrossRefPubMed
  16. Garbern JC, Lee RT. Mitochondria and metabolic transitions in cardiomyocytes: Lessons from development for stem cell-derived cardiomyocytes. Stem Cell Res Ther. 2021; 12(1): 177.
    CrossRefPubMed
  17. Hinata Y, Kagawa Y, Kubo H, et al. Importance of beating rate control for the analysis of drug effects on contractility in human induced pluripotent stem cell-derived cardiomyocytes. J Pharmacol Toxicol Methods. 2022; 118: 107228.
    CrossRefPubMed
  18. Hoekstra M, Mummery CL, Wilde AAM, et al. Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front Physiol. 2012; 3: 346.
    CrossRefPubMed
  19. Ma J, Guo L, Fiene SJ, et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol. 2011; 301(5): H2006–H2017.
    CrossRefPubMed
  20. Grancharova T, Gerbin KA, Rosenberg AB, et al. A comprehensive analysis of gene expression changes in a high replicate and open-source dataset of differentiating hiPSC-derived cardiomyocytes. Sci Rep. 2021; 11(1): 15845.
    CrossRefPubMed
  21. MacGrogan D, Münch J, de la Pompa JL. Notch and interacting signalling pathways in cardiac development, disease, and regeneration. Nat Rev Cardiol. 2018; 15(11): 685–704.
    CrossRefPubMed
  22. Zhou Q, Li L, Zhao B, et al. The hippo pathway in heart development, regeneration, and diseases. Circ Res. 2015; 116(8): 1431–1447.
    CrossRefPubMed
  23. Karbassi E, Fenix A, Marchiano S, et al. Cardiomyocyte maturation: Advances in knowledge and implications for regenerative medicine. Nat Rev Cardiol. 2020; 17(6): 341–359.
    CrossRefPubMed
  24. Yang H, Yang Y, Kiskin F, et al. Recent advances in regulating the proliferation or maturation of human-induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther. 2023; 14(1): 228.
    CrossRefPubMed
  25. Qiu XX, Liu Y, Zhang YF, et al. Rapamycin and CHIR99021 coordinate robust cardiomyocyte differentiation from human pluripotent stem cells via reducing p53-dependent apoptosis. J Am Heart Assoc. 2017; 6(10): e005295.
    CrossRefPubMed
  26. Fan C, Tang Y, Zhao M, et al. CHIR99021 and fibroblast growth factor 1 enhance the regenerative potency of human cardiac muscle patch after myocardial infarction in mice. J Mol Cell Cardiol. 2020; 141: 1–10.
    CrossRefPubMed
  27. Wu KH, Wang SuY, Xiao QR, et al. Small-molecule-based generation of functional cardiomyocytes from human umbilical cord-derived induced pluripotent stem cells. J Cell Biochem. 2019; 120(2): 1318–1327.
    CrossRefPubMed
  28. Yang X, Rodriguez ML, Leonard A, et al. Fatty acids enhance the maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cell Reports. 2019; 13(4): 657–668.
    CrossRefPubMed
  29. Horikoshi Y, Yan Y, Terashvili M, et al. Fatty acid-treated induced pluripotent stem cell-derived human cardiomyocytes exhibit adult cardiomyocyte-like energy metabolism phenotypes. Cells. 2019; 8(9): 1095.
    CrossRefPubMed
  30. Lin B, Lin X, Stachel M, et al. Culture in glucose-depleted medium supplemented with fatty acid and 3,3',5-triiodo-l-thyronine facilitates purification and maturation of human pluripotent stem cell-derived cardiomyocytes. Front Endocrinol (Lausanne). 2017; 8: 253.
    CrossRefPubMed
  31. Shimoji K, Yuasa S, Onizuka T, et al. G-CSF promotes the proliferation of developing cardiomyocytes in vivo and in derivation from ESCs and iPSCs. Cell Stem Cell. 2010; 6(3): 227–237.
    CrossRefPubMed
  32. Zwi-Dantsis L, Mizrahi I, Arbel G, et al. Scalable production of cardiomyocytes derived from c-Myc free induced pluripotent stem cells. Tissue Eng Part A. 2011; 17(7-8): 1027–1037.
    CrossRefPubMed
  33. Wobus AM, Wallukat G, Hescheler J. Pluripotent mouse embryonic stem cells are able to differentiate into cardiomyocytes expressing chronotropic responses to adrenergic and cholinergic agents and Ca2+ channel blockers. Differentiation. 1991; 48(3): 173–182.
    CrossRefPubMed
  34. Mauritz C, Schwanke K, Reppel M, et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation. 2008; 118(5): 507–517.
    CrossRefPubMed
  35. Bufi S, Santoro R. Three-dimensional iPSC-based in vitro cardiac models for biomedical and pharmaceutical research applications. Int J Mol Sci. 2024; 25(19): 10690.
    CrossRefPubMed
  36. Sacchetto C, Vitiello L, de Windt LJ, et al. Modeling cardiovascular diseases with hiPSC-derived cardiomyocytes in 2D and 3D cultures. Int J Mol Sci. 2020; 21(9): 3404.
    CrossRefPubMed
  37. Ronaldson-Bouchard K, Yeager K, Teles D, et al. Engineering of human cardiac muscle electromechanically matured to an adult-like phenotype. Nat Protoc. 2019; 14(10): 2781–2817.
    CrossRefPubMed
  38. Scuderi GJ, Butcher J. Naturally engineered maturation of cardiomyocytes. Front Cell Dev Biol. 2017; 5: 50.
    CrossRefPubMed
  39. Leucker TM, Bienengraeber M, Muravyeva M, et al. Endothelial-cardiomyocyte crosstalk enhances pharmacological cardioprotection. J Mol Cell Cardiol. 2011; 51(5): 803–811.
    CrossRefPubMed
  40. Yoshida S, Miyagawa S, Fukushima S, et al. Maturation of human induced pluripotent stem cell-derived cardiomyocytes by soluble factors from human mesenchymal stem cells. Mol Ther. 2018; 26(11): 2681–2695.
    CrossRefPubMed
  41. Kistamás K, Lamberto F, Vaiciuleviciute R, et al. The current state of realistic heart models for disease modelling and cardiotoxicity. Int J Mol Sci. 2024; 25(17): 9186.
    CrossRefPubMed
  42. Abulaiti M, Yalikun Y, Murata K, et al. Establishment of a heart-on-a-chip microdevice based on human iPS cells for the evaluation of human heart tissue function. Sci Rep. 2020; 10(1): 19201.
    CrossRefPubMed
  43. Tan Y, Coyle RC, Barrs RW, et al. Nanowired human cardiac organoid transplantation enables highly efficient and effective recovery of infarcted hearts. Sci Adv. 2023; 9(31): eadf2898.
    CrossRefPubMed
  44. Varzideh F, Mone P, Santulli G. Bioengineering strategies to create 3D cardiac constructs from human induced pluripotent stem cells. Bioengineering (Basel). 2022; 9(4): 168.
    CrossRefPubMed
  45. Kitsuka T, Itoh M, Amamoto S, et al. 2-Cl-C.OXT-A stimulates contraction through the suppression of phosphodiesterase activity in human induced pluripotent stem cell-derived cardiac organoids. PLoS One. 2019; 14(7): e0213114.
    CrossRefPubMed
  46. Veldhuizen J, Chavan R, Moghadas B, et al. Cardiac ischemia on-a-chip to investigate cellular and molecular response of myocardial tissue under hypoxia. Biomaterials. 2022; 281: 121336.
    CrossRefPubMed
  47. Lai BF, Lu RX, Davenport Huyer L, et al. A well plate-based multiplexed platform for incorporation of organoids into an organ-on-a-chip system with a perfusable vasculature. Nat Protoc. 2021; 16(4): 2158–2189.
    CrossRefPubMed
  48. Zhao Y, Rafatian N, Wang EY, et al. Engineering microenvironment for human cardiac tissue assembly in heart-on-a-chip platform. Matrix Biol. 2020; 85-86: 189–204.
    CrossRefPubMed
  49. Zhao Y, Rafatian N, Feric NT, et al. A platform for generation of chamber-specific cardiac tissues and disease modeling. Cell. 2019; 176(4): 913–927.e18.
    CrossRefPubMed
  50. Amano Y, Nishiguchi A, Matsusaki M, et al. Development of vascularized iPSC derived 3D-cardiomyocyte tissues by filtration Layer-by-Layer technique and their application for pharmaceutical assays. Acta Biomater. 2016; 33: 110–121.
    CrossRefPubMed
  51. Tadano K, Miyagawa S, Takeda M, et al. Cardiotoxicity assessment using 3D vascularized cardiac tissue consisting of human iPSC-derived cardiomyocytes and fibroblasts. Mol Ther Methods Clin Dev. 2021; 22: 338–349.
    CrossRefPubMed
  52. Schaefer JA, Guzman PA, Riemenschneider SB, et al. A cardiac patch from aligned microvessel and cardiomyocyte patches. J Tissue Eng Regen Med. 2018; 12(2): 546–556.
    CrossRefPubMed
  53. Iwoń Z, Krogulec E, Kierlańczyk A, et al. Hypoxia and re-oxygenation effects on human cardiomyocytes cultured on polycaprolactone and polyurethane nanofibrous mats. J Biol Eng. 2024; 18(1): 37.
    CrossRefPubMed
  54. Iwoń Z, Krogulec E, Kierlańczyk A, et al. Improving rodents and humans cardiac cell maturitythrough polycaprolactone and polyurethane nanofibers. Biomed Mater. 2024; 19(2).
    CrossRefPubMed
  55. Nikolova MP, Chavali MS. Recent advances in biomaterials for 3D scaffolds: A review. Bioact Mater. 2019; 4: 271–292.
    CrossRefPubMed
  56. Iwoń Z, Krogulec E, Tarnowska I, et al. Maturation of human cardiomyocytes derived from induced pluripotent stem cells (iPSC-CMs) on polycaprolactone and polyurethane nanofibrous mats. Sci Rep. 2024; 14(1): 12975.
    CrossRefPubMed
  57. Zhang M, Xu Y, Chen Y, et al. Three-dimensional poly-(ε-caprolactone) nanofibrous scaffolds promote the maturation of human pluripotent stem cells-induced cardiomyocytes. Front Cell Dev Biol. 2022; 10: 875278.
    CrossRefPubMed
  58. Silbernagel N, Körner A, Balitzki J, et al. Shaping the heart: Structural and functional maturation of iPSC-cardiomyocytes in 3D-micro-scaffolds. Biomaterials. 2020; 227: 119551.
    CrossRefPubMed
  59. LaBarge W, Mattappally S, Kannappan R, et al. Maturation of three-dimensional, hiPSC-derived cardiomyocyte spheroids utilizing cyclic, uniaxial stretch and electrical stimulation. PLoS One. 2019; 14(7): e0219442.
    CrossRefPubMed
  60. Ruan JL, Tulloch NL, Saiget M, et al. Mechanical stress promotes maturation of human myocardium from pluripotent stem cell-derived progenitors. Stem Cells. 2015; 33(7): 2148–2157.
    CrossRefPubMed
  61. Zhang X, Ye L, Xu H, et al. NRF2 is required for structural and metabolic maturation of human induced pluripotent stem cell-derived ardiomyocytes. Stem Cell Res Ther. 2021; 12(1): 208.
    CrossRefPubMed
  62. Mihic A, Li J, Miyagi Y, et al. The effect of cyclic stretch on maturation and 3D tissue formation of human embryonic stem cell-derived cardiomyocytes. Biomaterials. 2014; 35(9): 2798–2808.
    CrossRefPubMed
  63. Tulloch NL, Muskheli V, Razumova MV, et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res. 2011; 109(1): 47–59.
    CrossRefPubMed
  64. Hernández D, Millard R, Sivakumaran P, et al. Electrical stimulation promotes cardiac differentiation of human induced pluripotent stem cells. Stem Cells Int. 2016; 2016: 1718041.
    CrossRefPubMed
  65. Maihemuti W, Murata K, Abulaiti M, et al. Simultaneous electro-dynamic stimulation accelerates maturation of engineered cardiac tissues generated by human iPS cells. Biochem Biophys Res Commun. 2024; 733: 150605.
    CrossRefPubMed
  66. Masuda A, Kurashina Y, Tani H, et al. Maturation of human iPSC-derived cardiac microfiber with electrical stimulation device. Adv Healthc Mater. 2024; 13(27): e2303477.
    CrossRefPubMed
  67. Kroll K, Chabria M, Wang K, et al. Electro-mechanical conditioning of human iPSC-derived cardiomyocytes for translational research. Prog Biophys Mol Biol. 2017; 130(Pt B): 212–222.
    CrossRefPubMed
  68. Zhao M, Nakada Y, Wei Y, et al. Cyclin D2 overexpression enhances the efficacy of human induced pluripotent stem cell-derived cardiomyocytes for myocardial repair in a swine model of myocardial infarction. Circulation. 2021; 144(3): 210–228.
    CrossRefPubMed
  69. Zhu W, Zhao M, Mattapally S, et al. CCND2 overexpression enhances the regenerative potency of human induced pluripotent stem cell-derived cardiomyocytes: remuscularization of injured ventricle. Circ Res. 2018; 122(1): 88–96.
    CrossRefPubMed
  70. Lou X, Zhao M, Fan C, et al. N-cadherin overexpression enhances the reparative potency of human-induced pluripotent stem cell-derived cardiac myocytes in infarcted mouse hearts. Cardiovasc Res. 2020; 116(3): 671–685.
    CrossRefPubMed
  71. Kumar A, He S, Mali P. Systematic discovery of transcription factors that improve hPSC-derived cardiomyocyte maturation via temporal analysis of bioengineered cardiac tissues. APL Bioeng. 2023; 7(2): 026109.
    CrossRefPubMed
  72. Zhou J, Cui B, Wang X, et al. Overexpression of KCNJ2 enhances maturation of human-induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther. 2023; 14(1): 92.
    CrossRefPubMed
  73. Lieu DK, Fu JD, Chiamvimonvat N, et al. Mechanism-based facilitated maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Arrhythm Electrophysiol. 2013; 6(1): 191–201.
    CrossRefPubMed
  74. Kim YJ, Tamadon A, Kim YY, et al. Epigenetic regulation of cardiomyocyte differentiation from embryonic and induced pluripotent stem cells. Int J Mol Sci. 2021; 22(16): 8599.
    CrossRefPubMed
  75. Scesa G, Adami R, Bottai D. iPSC preparation and epigenetic memory: Does the tissue origin matter? Cells. 2021; 10(6): 1470.
    CrossRefPubMed
  76. Kim K, Zhao R, Doi A, et al. Epigenetic memory in induced pluripotent stem cells. Nature. 2010; 467(7313): 285–290.
    CrossRefPubMed
  77. Diez-Cuñado M, Wei Ke, Bushway PJ, et al. miRNAs that induce human cardiomyocyte proliferation converge on the hippo pathway. Cell Rep. 2018; 23(7): 2168–2174.
    CrossRefPubMed
  78. Bian W, Chen W, Nguyen T, et al. miR-199a overexpression enhances the potency of human induced-pluripotent stem-cell-derived cardiomyocytes for myocardial repair. Front Pharmacol. 2021; 12: 673621.
    CrossRefPubMed
  79. Xu F, Yang J, Shang J, et al. MicroRNA-302d promotes the proliferation of human pluripotent stem cell-derived cardiomyocytes by inhibiting in the Hippo pathway. Clin Sci (Lond). 2019; 133(13): 1387–1399.
    CrossRefPubMed
  80. Miklas JW, Clark E, Levy S, et al. TFPa/HADHA is required for fatty acid beta-oxidation and cardiolipin re-modeling in human cardiomyocytes. Nat Commun. 2019; 10(1): 4671.
    CrossRefPubMed
  81. Kuppusamy KT, Jones DC, Sperber H, et al. Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes. Proc Natl Acad Sci U S A. 2015; 112(21): E2785–E2794.
    CrossRefPubMed
  82. Fu JD, Rushing SN, Lieu DK, et al. Distinct roles of microRNA-1 and -499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes. PLoS One. 2011; 6(11): e27417.
    CrossRefPubMed
  83. Wang Z, Cui M, Shah AM, et al. Mechanistic basis of neonatal heart regeneration revealed by transcriptome and histone modification profiling. Proc Natl Acad Sci U S A. 2019; 116(37): 18455–18465.
    CrossRefPubMed
  84. Gilsbach R, Schwaderer M, Preissl S, et al. Distinct epigenetic programs regulate cardiac myocyte development and disease in the human heart in vivo. Nat Commun. 2018; 9(1): 391.
    CrossRefPubMed
  85. Biermann M, Cai W, Lang Di, et al. Epigenetic priming of human pluripotent stem cell-derived cardiac progenitor cells accelerates cardiomyocyte maturation. Stem Cells. 2019; 37(7): 910–923.
    CrossRefPubMed
  86. Deogharia M, Venegas-Zamora L, Agrawal A, et al. Histone demethylase KDM5 regulates cardiomyocyte maturation by promoting fatty acid oxidation, oxidative phosphorylation, and myofibrillar organization. Cardiovasc Res. 2024; 120(6): 630–643.
    CrossRefPubMed
  87. Li C, Zhang Y, Shen J, et al. Cfp1 controls cardiomyocyte maturation by modifying histone H3K4me3 of structural, metabolic, and contractile related genes. Adv Sci (Weinh). 2024; 11(11): e2305992.
    CrossRefPubMed
  88. Han Z, Wang X, Xu Z, et al. ALKBH5 regulates cardiomyocyte proliferation and heart regeneration by demethylating the mRNA of YTHDF1. Theranostics. 2021; 11(6): 3000–3016.
    CrossRefPubMed
  89. Dias TP, Pinto SN, Santos JI, et al. Biophysical study of human induced Pluripotent Stem Cell-Derived cardiomyocyte structural maturation during long-term culture. Biochem Biophys Res Commun. 2018; 499(3): 611–617.
    CrossRefPubMed
  90. Lundy SD, Zhu WZ, Regnier M, et al. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 2013; 22(14): 1991–2002.
    CrossRefPubMed
  91. Ebert A, Joshi AU, Andorf S, et al. Proteasome-Dependent regulation of distinct metabolic states during long-term culture of human iPSC-derived cardiomyocytes. Circ Res. 2019; 125(1): 90–103.
    CrossRefPubMed
  92. Lewandowski J, Rozwadowska N, Kolanowski TJ, et al. The impact of in vitro cell culture duration on the maturation of human cardiomyocytes derived from induced pluripotent stem cells of myogenic origin. Cell Transplant. 2018; 27(7): 1047–1067.
    CrossRefPubMed
  93. Kamakura T, Makiyama T, Sasaki K, et al. Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. Circ J. 2013; 77(5): 1307–1314.
    CrossRefPubMed
  94. Kumar N, Dougherty JA, Manring HR, et al. Assessment of temporal functional changes and miRNA profiling of human iPSC-derived cardiomyocytes. Sci Rep. 2019; 9(1): 13188.
    CrossRefPubMed
  95. Fukushima H, Yoshioka M, Kawatou M, et al. Specific induction and long-term maintenance of high purity ventricular cardiomyocytes from human induced pluripotent stem cells. PLoS One. 2020; 15(11): e0241287.
    CrossRefPubMed
  96. Seibertz F, Sutanto H, Dülk R, et al. Electrophysiological and calcium-handling development during long-term culture of human-induced pluripotent stem cell-derived cardiomyocytes. Basic Res Cardiol. 2023; 118(1): 14.
    CrossRefPubMed
  97. Li Q, Wang J, Wu Q, et al. Perspective on human pluripotent stem cell-derived cardiomyocytes in heart disease modeling and repair. Stem Cells Transl Med. 2020; 9(10): 1121–1128.
    CrossRefPubMed
  98. Campuzano O, Beltrán-Alvarez P, Iglesias A, et al. Genetics and cardiac channelopathies. Genet Med. 2010; 12(5): 260–267.
    CrossRefPubMed
  99. Brandão KO, van den Brink L, Miller DC, et al. Isogenic sets of hiPSC-CMs harboring distinct KCNH2 mutations differ functionally and in susceptibility to drug-induced arrhythmias. Stem Cell Reports. 2020; 15(5): 1127–1139.
    CrossRefPubMed
  100. Takaki T, Inagaki A, Chonabayashi K, et al. Optical recording of action potentials in human induced pluripotent stem cell-derived cardiac single cells and monolayers generated from long QT syndrome type 1 patients. Stem Cells International. 2019; 2019: 7532657.
    CrossRefPubMed
  101. Crotti L, Neves R, Dagradi F, et al. From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome type 2. Eur Heart J. 2019; 40(23): 1832–1836.
    CrossRefPubMed
  102. Mehta A, Ramachandra CJA, Singh P, et al. Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model. Eur Heart J. 2018; 39(16): 1446–1455.
    CrossRefPubMed
  103. Ma D, Wei H, Lu J, et al. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther. 2015; 6(1): 39.
    CrossRefPubMed
  104. Wang Y, Liang P, Lan F, et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J Am Coll Cardiol. 2014; 64(5): 451–459.
    CrossRefPubMed
  105. Itzhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011; 471(7337): 225–229.
    CrossRefPubMed
  106. Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010; 363(15): 1397–1409.
    CrossRefPubMed
  107. Stutzman MJ, Kim CS, Tester DJ, et al. Characterization of N-terminal RYR2 variants outside CPVT1 hotspot regions using patient iPSCs reveal pathogenesis and therapeutic potential. Stem Cell Reports. 2022; 17(9): 2023–2036.
    CrossRefPubMed
  108. Acimovic I, Refaat MM, Moreau A, et al. Post-translational modifications and diastolic calcium leak associated to the novel RyR2-D3638A mutation lead to CPVT in patient-specific hiPSC-derived cardiomyocytes. J Clin Med. 2018; 7(11): 423.
    CrossRefPubMed
  109. Fatima A, Xu G, Shao K, et al. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem. 2011; 28(4): 579–592.
    CrossRefPubMed
  110. Zhong R, Schimanski T, Zhang F, et al. A preclinical study on Brugada syndrome with a CACNB2 variant using human cardiomyocytes from induced pluripotent stem cells. Int J Mol Sci. 2022; 23(15).
    CrossRefPubMed
  111. Zhu Y, Wang L, Cui C, et al. Pathogenesis and drug response of iPSC-derived cardiomyocytes from two Brugada syndrome patients with different Nav1.5-subunit mutations. J Biomed Res. 2021; 35(5): 395–407.
    CrossRefPubMed
  112. Li W, Stauske M, Luo X, et al. Disease phenotypes and mechanisms of iPSC-derived cardiomyocytes from brugada syndrome patients with a loss-of-function SCN5A mutation. Front Cell Dev Biol. 2020; 8: 592893.
    CrossRefPubMed
  113. Wexler RK, Elton T, Pleister A, et al. Cardiomyopathy: An overview. Am Fam Physician. 2009; 79(9): 778–784.
    PubMed
  114. Mori H, Xu D, Shimoda Y, et al. Metabolic remodeling and calcium handling abnormality in induced pluripotent stem cell-derived cardiomyocytes in dilated phase of hypertrophic cardiomyopathy with MYBPC3 frameshift mutation. Sci Rep. 2024; 14(1): 15422.
    CrossRefPubMed
  115. Escribá R, Larrañaga-Moreira JM, Richaud-Patin Y, et al. iPSC-based modeling of variable clinical presentation in hypertrophic cardiomyopathy. Circ Res. 2023; 133(2): 108–119.
    CrossRefPubMed
  116. Korover N, Etzion S, Cherniak A, et al. Functional defects in hiPSCs-derived cardiomyocytes from patients with a PLEKHM2-mutation associated with dilated cardiomyopathy and left ventricular non-compaction. Biol Res. 2023; 56(1): 34.
    CrossRefPubMed
  117. Dai Y, Amenov A, Ignatyeva N, et al. Troponin destabilization impairs sarcomere-cytoskeleton interactions in iPSC-derived cardiomyocytes from dilated cardiomyopathy patients. Sci Rep. 2020; 10(1): 209.
    CrossRefPubMed
  118. Caspi O, Huber I, Gepstein A, et al. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. Circ Cardiovasc Genet. 2013; 6(6): 557–568.
    CrossRefPubMed
  119. Prondzynski M, Bortolin RH, Berkson P, et al. Efficient and reproducible generation of human iPSC-derived cardiomyocytes using a stirred bioreactor. bioRxiv. 2024.
    CrossRefPubMed
  120. Lin Y, Sato N, Hong S, et al. Long-term engraftment and maturation of autologous iPSC-derived cardiomyocytes in two rhesus macaques. Cell Stem Cell. 2024; 31(7): 974–988.e5.
    CrossRefPubMed
  121. Andrysiak K, Stępniewski J, Dulak J. Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research. Pflugers Arch. 2021; 473(7): 1061–1085.
    CrossRefPubMed
  122. Yadid M, Oved H, Silberman E, et al. Bioengineering approaches to treat the failing heart: From cell biology to 3D printing. Nat Rev Cardiol. 2022; 19(2): 83–99.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2025 Via Medica Regulations Cookie policy Privacy Statement Legal Note